Drug Information

Drug General Information
Drug ID
D0H1EA
Former ID
DNCL002271
Drug Name
TH-302
Drug Type
Small molecular drug
Indication Soft tissue sarcoma [ICD9: 171; ICD10:C00-D49] Phase 2 [523562], [543252]
Company
Threshold Pharmaceuticals
Formula
C9H16Br2N5O4P
InChI
InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
InChIKey
UGJWRPJDTDGERK-UHFFFAOYSA-N
PubChem Compound ID
11984561
PubChem Substance ID
17435611, 24494978, 37433028, 78012247, 103566630, 123055416, 135263747, 136340374, 136345844, 136367499, 137201888, 140837709, 152159580, 152258249, 160644555, 160647085, 162011928, 172919691, 174531482, 185990494, 198939688, 228474748, 240626081, 242060051, 247974941, 252166895, 252552913
Target and Pathway
Target(s) Human DNA Target Info Modulator
References
Ref 523562ClinicalTrials.gov (NCT01403610) Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab. U.S. National Institutes of Health.
Ref 543252(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8695).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.